Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Cancer ; 2024 Jul 10.
Article in English | MEDLINE | ID: mdl-38985794

ABSTRACT

BACKGROUND: The management of early breast cancer (BC) has witnessed an uprise in the use of neoadjuvant therapy and a remarkable reshaping of the systemic therapy postneoadjuvant treatment in the last few years, with the evolution of many controversial clinical situations that require consensus. METHODS: During the 14th Breast-Gynecological and Immuno-Oncology International Cancer Conference held in Egypt in 2022, a panel of 44 BC experts from 13 countries voted on statements concerning debatable challenges in the neo/adjuvant treatment setting. The recommendations were subsequently updated based on the most recent data emerging. A modified Delphi approach was used to develop this consensus. A consensus was achieved when ≥75% of voters selected an answer. RESULTS AND CONCLUSIONS: The consensus recommendations addressed different escalation and de-escalation strategies in the setting of neoadjuvant therapy for early BC. The recommendations recapitulate the available clinical evidence and expert opinion to individualize patient management and optimize therapy outcomes. Consensus was reached in 63% of the statements (52/83), and the rationale behind each statement was clarified.

2.
Eur J Breast Health ; 18(3): 205-221, 2022 Jul.
Article in English | MEDLINE | ID: mdl-35855198

ABSTRACT

Objective: Therapeutic management of ductal carcinoma in situ (DCIS) is heterogeneous among countries worldwide, and some treatment indications are still controversial. To investigate DCIS management in different countries; identify both consensual practices and controversial topics; and survey opinions about the future management of DCIS. Materials and Methods: The Senologic International Society network members participated to an online survey using a questionnaire, between November 2021 and February 2022. Results: Twenty-two responses from 20 different countries showed that organized breast cancer screening programs were present for 87% participants, and DCIS cases represented 13.7% of all breast cancers. Most participants used the grade classification (100%), the morphological classification (78%) and performed immunohistochemistry assays (73%). In case of conservative treatment, the mean re-excision rate was 10.3% and clear margins of mean 2.5 mm were considered healthy. Radical mastectomy rate was 35.5% with a breast reconstruction rate of 53%. Tumor bed boost indications were heterogeneous, and 73% of participants indicated hormone therapy for hormone-positive DCIS. Surgery and radiotherapy omission for some low-risk DCIS were considered by 73% of participants. Multigene assays were used by 43% of participants. Concerning future changes in DCIS management, participants mostly answered surgical de-escalation (48%), radiotherapy de-escalation (35) and/or active surveillance for some cases (22%). Conclusion: This survey provided an overview of the current practices of DCIS management worldwide. It showed that some areas are rather consensual: incidence increases over time, treatment in young women, pathological classifications, definition of healthy margins, the skin-sparing mastectomy and immediate breast reconstruction. However, some topics are still debated and result in heterogeneous practices, such as evolution in the age of diagnosis, the benefit of de-escalation in low-risk DCIS among elderly women, indications for hormone therapy, radiotherapy omission, or multigene assays. Further evidence is needed to reach consensus on these points, and innovative approaches are still under evaluation in clinical trials. The International Senologic Society, by its members, encourages precision medicine and personalized treatments for DCIS, to avoid overtreatment and overdiagnosis, and provide better healthcare to women with DCIS.

3.
Eur J Breast Health ; 17(2): 188-196, 2021 Apr.
Article in English | MEDLINE | ID: mdl-33870120

ABSTRACT

OBJECTIVE: In early 2020, the spread of coronavirus disease-2019 (COVID-19) led the World Health Organization to declare this disease a pandemic. Initial epidemiological data showed that patients with cancer were at high risk of developing severe forms of COVID-19. National scientific societies published recommendations modifying the patients' breast cancer (BC) management to preserve, in theory, quality oncologic care, avoiding the increased risk of contamination. The Senology International Society (SIS) decided to take an inventory of the actions taken worldwide. This study investigates COVID-19-related changes concerning BC management and analyzes the will to maintain them after the pandemic, evaluating their oncological safety consequences. MATERIALS AND METHODS: SIS network members participated in an online survey using a questionnaire (Microsoft® Forms) from June 15th to July 31st, 2020. RESULTS: Forty-five responses from 24 countries showed that screening programs had been suspended (68%); magnetic resonance imagines were postponed (73%); telemedicine was preferred when possible (71%). Surgeries were postponed: reconstructive (77%), for benign diseases (84%), and in patients with significant comorbidities (66%). Chemotherapy and radiotherapy protocols had been adapted in 28% of patients in both. Exception for telemedicine (34%), these changes in practice should not be continued. CONCLUSION: The SIS survey showed significant changes in BC's diagnosis and treatment during the first wave of the COVID-19 pandemic, but most of these changes should not be maintained. Indeed, women have fewer severe forms of COVID-19 and are less likely to die than men. The risk of dying from COVID-19 is more related to the presence of comorbidities and age than to BC. Stopping screening and delaying treatment leads to more advanced stages of BC. Only women aged over 65 with BC under treatment and comorbidities require adaptation of their cancer management.

4.
Int Urol Nephrol ; 52(3): 455-460, 2020 Mar.
Article in English | MEDLINE | ID: mdl-31745707

ABSTRACT

PURPOSE: To evaluate if HoLEP is a viable option for male patients with medication-refractory urinary symptoms due to an enlarged prostate who are surgical candidates, but do not accept blood product transfusion. MATERIALS AND METHODS: Between August 2008 and March 2019, nine Jehovah's Witness patients were undergoing HoLEP for relief of lower urinary tract symptoms and urinary retention. We described change in hemoglobin, change in PSA, enucleated prostate weight, enucleation and morcellation times, length of stay, and postoperative retention rate. RESULTS: The average age was 71.4 years (range 53-87). Urinary retention requiring catheterization was present in seven patients (78%). Two patients had a known diagnosis of prostate cancer preoperatively. The mean preoperative PSA on average was 21.6 ng/dL. Patients had a wide range of gland sizes, with a mean enucleated weight of 141 g (range 18-344 g). Mean reduction in hemoglobin was 16.9% following HoLEP. All patients managed to void postoperatively. All but one patient went home on postoperative day 1, and this patient went home on postoperative day 2. No patients required blood product transfusion or return to the operating room for clot irrigation postoperatively. CONCLUSION: HoLEP is a reasonable option for Jehovah's Witness and other patients with contraindications to blood product transfusion requiring surgical management of urinary symptoms due to enlarged prostate.


Subject(s)
Blood Loss, Surgical/prevention & control , Laser Therapy , Lasers, Solid-State/therapeutic use , Postoperative Complications , Prostatic Hyperplasia , Urinary Retention , Aged , Humans , Jehovah's Witnesses , Laser Therapy/adverse effects , Laser Therapy/instrumentation , Laser Therapy/methods , Lower Urinary Tract Symptoms/diagnosis , Lower Urinary Tract Symptoms/etiology , Male , Organ Size , Outcome and Process Assessment, Health Care , Postoperative Complications/diagnosis , Postoperative Complications/therapy , Prostate/pathology , Prostatic Hyperplasia/diagnosis , Prostatic Hyperplasia/physiopathology , Prostatic Hyperplasia/therapy , Urinary Catheterization/methods , Urinary Retention/diagnosis , Urinary Retention/etiology , Urinary Retention/therapy
5.
BMJ ; 345: e8268, 2012 Dec 14.
Article in English | MEDLINE | ID: mdl-23247979

ABSTRACT

OBJECTIVE: To investigate the true character of the harem conspiracy described in the Judicial Papyrus of Turin and determine whether Ramesses III was indeed killed. DESIGN: Anthropological, forensic, radiological, and genetic study of the mummies of Ramesses III and unknown man E, found together and taken from the 20th dynasty of ancient Egypt (circa 1190-1070 BC). RESULTS: Computed tomography scans revealed a deep cut in Ramesses III's throat, probably made by a sharp knife. During the mummification process, a Horus eye amulet was inserted in the wound for healing purposes, and the neck was covered by a collar of thick linen layers. Forensic examination of unknown man E showed compressed skin folds around his neck and a thoracic inflation. Unknown man E also had an unusual mummification procedure. According to genetic analyses, both mummies had identical haplotypes of the Y chromosome and a common male lineage. CONCLUSIONS: This study suggests that Ramesses III was murdered during the harem conspiracy by the cutting of his throat. Unknown man E is a possible candidate as Ramesses III's son Pentawere.


Subject(s)
Famous Persons , Homicide/history , Mummies/history , Neck Injuries/history , Adolescent , DNA Fingerprinting , Egypt, Ancient , Haplotypes , History, Ancient , Humans , Male , Mummies/diagnostic imaging , Neck Injuries/diagnostic imaging , Tomography, X-Ray Computed , Wounds, Penetrating/diagnostic imaging , Wounds, Penetrating/history , Young Adult
6.
JAMA ; 303(7): 638-47, 2010 Feb 17.
Article in English | MEDLINE | ID: mdl-20159872

ABSTRACT

CONTEXT: The New Kingdom in ancient Egypt, comprising the 18th, 19th, and 20th dynasties, spanned the mid-16th to the early 11th centuries bc. The late 18th dynasty, which included the reigns of pharaohs Akhenaten and Tutankhamun, was an extraordinary time. The identification of a number of royal mummies from this era, the exact relationships between some members of the royal family, and possible illnesses and causes of death have been matters of debate. OBJECTIVES: To introduce a new approach to molecular and medical Egyptology, to determine familial relationships among 11 royal mummies of the New Kingdom, and to search for pathological features attributable to possible murder, consanguinity, inherited disorders, and infectious diseases. DESIGN: From September 2007 to October 2009, royal mummies underwent detailed anthropological, radiological, and genetic studies as part of the King Tutankhamun Family Project. Mummies distinct from Tutankhamun's immediate lineage served as the genetic and morphological reference. To authenticate DNA results, analytical steps were repeated and independently replicated in a second ancient DNA laboratory staffed by a separate group of personnel. Eleven royal mummies dating from circa 1410-1324 bc and suspected of being kindred of Tutankhamun and 5 royal mummies dating to an earlier period, circa 1550-1479 bc, were examined. MAIN OUTCOME MEASURES: Microsatellite-based haplotypes in the mummies, generational segregation of alleles within possible pedigree variants, and correlation of identified diseases with individual age, archeological evidence, and the written historical record. RESULTS: Genetic fingerprinting allowed the construction of a 5-generation pedigree of Tutankhamun's immediate lineage. The KV55 mummy and KV35YL were identified as the parents of Tutankhamun. No signs of gynecomastia and craniosynostoses (eg, Antley-Bixler syndrome) or Marfan syndrome were found, but an accumulation of malformations in Tutankhamun's family was evident. Several pathologies including Köhler disease II were diagnosed in Tutankhamun; none alone would have caused death. Genetic testing for STEVOR, AMA1, or MSP1 genes specific for Plasmodium falciparum revealed indications of malaria tropica in 4 mummies, including Tutankhamun's. These results suggest avascular bone necrosis in conjunction with the malarial infection as the most likely cause of death in Tutankhamun. Walking impairment and malarial disease sustained by Tutankhamun is supported by the discovery of canes and an afterlife pharmacy in his tomb. CONCLUSION: Using a multidisciplinary scientific approach, we showed the feasibility of gathering data on Pharaonic kinship and diseases and speculated about individual causes of death.


Subject(s)
DNA Fingerprinting , Malaria, Falciparum/pathology , Mummies/pathology , Osteonecrosis/pathology , Cause of Death , Clubfoot , Consanguinity , Egypt, Ancient , Female , History, Ancient , Humans , Malaria, Falciparum/genetics , Male , Microsatellite Repeats , Pedigree
7.
J Dermatolog Treat ; 20(4): 203-7, 2009.
Article in English | MEDLINE | ID: mdl-19085266

ABSTRACT

BACKGROUND: Contact dermatitis accounts for approximately 50% of occupational illnesses and is responsible for an estimated 25% of all lost work days. OBJECTIVE: To evaluate the usefulness of using psycho-behavioural assessment in identifying the influence of depression on the treatment of occupational dermatoses. METHODS: The study was conducted on 250 furnace workers exposed to arsenic in Helwan district, Cairo, Egypt. A complete history including occupational history and medical assessment were done followed by undergoing a neurobehavioural battery. The battery included the Beck Depression Inventory, personality tests, and cognitive tests. Patients received a class 1 topical corticosteroid, potassium permanganate soaks, and oral antihistamine for 6 months and after a change of work they were re-examined. RESULTS: After 6 months, patients were divided into two groups according to response to therapy: group A (responders) and group B (non-responders). The psycho-behavioural battery was compared between both groups and showed a significant difference, suggesting the influence of depression on the outcome of treatment among group B patients. CONCLUSION: Psycho-behavioural analysis of occupational dermatitis patients before starting treatment is recommended. All occupational dermatitis patients showing a bad psycho-behavioural test should be psychologically treated with psychotherapy or antidepressants.


Subject(s)
Depression/psychology , Dermatitis, Occupational/psychology , Arsenic/adverse effects , Behavior , Cognition , Depression/complications , Depression/diagnosis , Dermatitis, Contact/etiology , Dermatitis, Occupational/etiology , Dermatitis, Occupational/therapy , Humans , Male , Middle Aged , Occupational Exposure , Personality
8.
J Egypt Natl Canc Inst ; 20(4): 313-22, 2008 Dec.
Article in English | MEDLINE | ID: mdl-20571589

ABSTRACT

UNLABELLED: The global health community faces a challenge with breast cancer being the most common cause of cancer related death among women around the globe. Since breast cancer's pathogenesis is poorly understood, primary prevention is still a distant goal. Thus secondary prevention through early detection is the only feasible approach at present. With this strong conviction, the launching of the first Egyptian national screening program "Women Health Outreach Program" (WHOP), was announced on October 30th 2007. This project is a government- funded program that offers free breast screening for all Egyptian women above the age of 45 years. In addition to free mammograms, the program gives the participants a chance to be screened for diabetes, hypertension and obesity as well. Positively detected cases are also offered the option of free management. During the period from October 30th, 2007, up to February 9th, 2009, 20, 098 women in Cairo, Alexandria and Suez governorates were screened for breast cancer, diabetes, hypertension and obesity through the program. In this article we will represent the achievements, challenges and services delivered by WHOP. KEY WORDS: Breast cancer - Breast screening - Early detection - Breast biopsy.

SELECTION OF CITATIONS
SEARCH DETAIL
...